J Agustin Lacson, MD in Avon Park, FL - Medicare Infectious Disease

J Agustin Lacson, MD is a medicare enrolled "Internal Medicine - Infectious Disease" physician in Avon Park, Florida. He graduated from medical school in 1990 and has 34 years of diverse experience with area of expertise as Infectious Disease. His current practice location is 3300 Us 27 S, Avon Park, Florida. You can reach out to his office (for appointments etc.) via phone at (863) 385-6700.

J Agustin Lacson is licensed to practice in Florida (license number ME0072358) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1831153055.

Contact Information

	J Agustin Lacson, MD
	3300 Us 27 S, Avon Park, FL 33825-9701
	(863) 385-6700
	Not Available

Physician's Profile

Full Name	J Agustin Lacson
Gender	Male
Speciality	Infectious Disease
Experience	34 Years
Location	3300 Us 27 S, Avon Park, Florida
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

J Agustin Lacson graduated from medical school in 1990

NPI Data:

NPI Number: 1831153055
Provider Enumeration Date: 04/14/2006
Last Update Date: 09/08/2022

Medicare PECOS Information:

PECOS PAC ID: 9739070855
Enrollment ID: I20040320000036

Medical Identifiers

Medical identifiers for J Agustin Lacson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1831153055	NPI	-	NPPES
44661	Other	FL	BLUE CROSS BLUE SHIELD
024129700	Medicaid	FL
110241195	Other	FL	RAILROAD MEDICARE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RI0200X	Internal Medicine - Infectious Disease	ME0072358 (Florida)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Adventhealth Sebring	Sebring, FL	Hospital
Winter Haven Hospital	Winter haven, FL	Hospital
Adventhealth Wauchula	Wauchula, FL	Hospital

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. J Agustin Lacson allows following entities to bill medicare on his behalf.

Entity Name	J. Agustin Lacson M.d. Inc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1619931821 PECOS PAC ID: 3375434491 Enrollment ID: O20040320000024

News Archive

Lucideon holds free webinar

Lucideon, the international materials technology company, is hosting a free webinar entitled ‘The Benefits of Using Ceramic Reflectance Standards to Calibrate Instruments and Control Colour in the Healthcare Industry'.

BubR1 and its associated regulators promising targets for aging disorders and cancer

A new series of studies in mouse models by Mayo Clinic researchers uncovered that the aging process is characterized by high rates of whole-chromosome losses and gains in various organs, including heart, muscle, kidney and eye, and demonstrate that reducing these rates slows age-related tissue deterioration and promotes a healthier life span. The findings appear in today's online issue of Nature Cell Biology.

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima).

Entity Name	Dchd Health Care Professionals Llc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1346563897 PECOS PAC ID: 6800910365 Enrollment ID: O20100907000065

Lucideon holds free webinar

BubR1 and its associated regulators promising targets for aging disorders and cancer

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Entity Name	Desoto County Hospital District
Entity Type	Part B Supplier - Hospital Department(s)
Entity Identifiers	NPI Number: 1528387842 PECOS PAC ID: 0840485637 Enrollment ID: O20101105000725

Lucideon holds free webinar

BubR1 and its associated regulators promising targets for aging disorders and cancer

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. J Agustin Lacson is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
J Agustin Lacson, MD Po Box 7514, Sebring, FL 33872-0109 Ph: (863) 385-6700	J Agustin Lacson, MD 3300 Us 27 S, Avon Park, FL 33825-9701 Ph: (863) 385-6700

News Archive

Lucideon holds free webinar

BubR1 and its associated regulators promising targets for aging disorders and cancer

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Internal Medicine Doctors in Avon Park, FL

Prixit Sharma, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1005 W Circle St, Avon Park, FL 33825 Phone: 863-453-5500 Fax: 863-453-5566
Ms. Christina Maria Stump, ARNP Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 596 Us Highway 27 N, Avon Park, FL 33825 Phone: 863-314-8555 Fax: 863-453-3400
Jennie Leclair Spencer, ARNP,FNP Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 596 Us Highway 27 N, Avon Park, FL 33825 Phone: 863-314-8555
Dr. Stanley Andrew Tan, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1005 W Circle St, Avon Park, FL 33825 Phone: 863-453-5500 Fax: 863-453-5566
Dr. Fernando Melocoton Abanilla, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3030 Us 27 S, Avon Park, FL 33825 Phone: 863-314-0555 Fax: 863-314-0806
Delores R Garcia-chung, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 950 County Road 17a W, Avon Park, FL 33825 Phone: 863-452-3000 Fax: 863-452-3029

J Agustin Lacson, MD - Medicare Infectious Disease in Avon Park, FL

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Medicare Reassignments

Lucideon holds free webinar

BubR1 and its associated regulators promising targets for aging disorders and cancer

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Lucideon holds free webinar

BubR1 and its associated regulators promising targets for aging disorders and cancer

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Lucideon holds free webinar

BubR1 and its associated regulators promising targets for aging disorders and cancer

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Lucideon holds free webinar

BubR1 and its associated regulators promising targets for aging disorders and cancer

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Internal Medicine Doctors in Avon Park, FL